top of page

Q1 2023 Newsletter: Vita Group Medical Device Incubator

Updated: Sep 22, 2023

Welcome to our 2023 Q1 Vita Group Medical Device newsletter! We hope this finds you well and that you're excited to dive into the latest updates from Vita Group. In this edition, we have some exciting announcements to share with you, including new services, project updates, and an important new hire to the company.

As always, we thank you for your continued support and we hope you enjoy this latest edition.



Brekka & StingRay Coming Soon:


We are excited to announce that Brekka and StingRay are now commercialized and are available for sale. These two user-friendly implant delivery devices are designed to make the process of implant delivery easier and more efficient for plastic surgeons. The StingRay quantities are expected to be ready for distribution at the end of March, and Brekka’s will be ready mid-April, which is great news for those who have been eagerly awaiting their arrival.

Pouring implant into Brekka device

The Brekka Implant Delivery Device is versatile, with three different configurations to choose from and user-friendly handles. These features allow you to select the best option based on the implant type and efficiently deliver implants.




StingRay device ready for implant delivery

The StingRay Implant Delivery Device provides precise and controlled delivery, ensuring the accurate placement of implants. The folding design of StingRay enables you to modify the device's size according to the implant.


Stay updated on Brekka and StingRay by following our social media pages here:


Vita Group Medical Device Manufacturing Services:


Vita Group has recently announced the acquisition of a manufacturing company, which will enable us to expand our services to include rapid prototyping, precision machining, secondary operations, manufacturing, process validation, sterile barrier packaging, and supply chain management, and injection molding.


Manufacturing facility

Injection Molding is especially important because molding is critical to maintaining consistent quality, control costs and ultimately improves the results of the device. This process involves the use of specialized equipment to create complex shapes and designs with high accuracy and precision. With this service, Vita Group can produce parts that are more intricate and detailed than ever before.

These new services will allow Vita Group to provide a more comprehensive range of solutions to their clients in various industries. Our company's focus on quality and efficiency will ensure that our manufacturing services meet the highest standards and deliver exceptional results. Overall, this acquisition represents an exciting development for Vita Group and our clients. To learn more in depth about these manufacturing services, you can read about it here: https://www.vitagroup.io/post/press-release-vita-group-implements-new-services-in-2023



New Location Update:


Vita Group is expanding our operations by making an offer on a new building in Woodbury, MN. The potential location spans over 155,000 sqft with 35,000 sqft for manufacturing and will serve as the new home for the engineering team, manufacturing floor with equipment, break rooms, multiple offices, and other amenities. The move is expected to enhance our company's efficiency while providing a productive work environment for our employees. This news represents a significant investment for Vita Group as we seek to expand our footprint in the medical device industry.


Project Updates:


22 total projects

Vita Group is thrilled to announce the approval of 22 projects since establishment. Out of these, nine are currently in acceleration and four have already been commercialized. We aim to expand our headquarters and introduce a manufacturing arm to reduce the time taken from initial concept to commercialization. We'd like to express our gratitude towards our existing clients for trusting their ideas with our team and we look forward to offering more services and delivering better medical device innovations to benefit patients.


New Hire, VP Regulatory:


Dani Gibbs VP Regulatory

Vita Group has recently hired a new employee, Dani Gibbs, as the Vice President of Regulatory. With her extensive experience in regulatory affairs and certification as a Lead Auditor by AAMI, she brings a wealth of knowledge and expertise to the company. Dani’s position as VP of Regulatory means that Vita Group now has an in-house specialist in regulatory affairs which will support our mission to bring medical devices to the market as fast as possible.


New Post Recovery MD Kit

Vita Group has partnered with Dr. Karan Chopra to create PostRecoveryMD, an all-in-one recovery kit with products selected by surgeons to bring ease and reliability to patient recovery. A variety of kits are offered for specific surgeries, such as facelift, breast augmentation, and tummy tuck operations. And now, we are adding another kit to the collection– a C-section kit.


Post Recovery MD with products

The newly offered C-section kit focuses on reducing swelling and promoting healing. The products included in the kit have been carefully selected based on their effectiveness in helping women recover from a C-section. This means that patients can trust that they are getting high-quality products that will help them recover as quickly as possible. Some examples of products provided in this kit include Blessed Thistle, ice packs, and Calmoseptine ointment.


Ultimately, the C-section kit is highly beneficial for mothers who have undergone a C-section as it provides access to an all-in-one recovery kit with high quality products selected by surgeons so mothers can get back to enjoying life with their new bundle of joy.


You can read more about Post Recovery MD’s C-section kit here: https://www.vitagroup.io/post/a-new-product-for-c-section-recovery-coming-soon


 

Thank you for reading this edition of Q1 2023 Newsletter. We hope you enjoyed the updates, and you can expect our Q2 2023 Newsletter at the end of June. To learn more, visit us at www.vitagroup.io.


If you have questions about the medical incubation process and want to learn more, book a time to meet with our CEO Jason Scherer.

Comments


bottom of page